FibroBiologics announced that the USPTO has granted a patent for methods using fibroblasts to enhance the survival and function of transplanted pancreatic islets in Type 1 diabetes treatment. This innovation addresses the challenge of poor islet engraftment, potentially increasing the efficiency of donor tissue use and expanding patient access to cell-based therapies. The technology may also have broader applications in other cell and tissue transplantation procedures. FibroBiologics aims to improve outcomes for patients by leveraging fibroblast properties to support tissue regeneration and therapeutic efficacy.
Yvonne Wassenaar, a director at Rubrik, sold 721 shares at a price of $75 each just before the company's stock experienced a significant rally. This sale occurred ahead of the stock's upward movement, which may be of interest to investors tracking in...
The First Trust RBA American Industrial Renaissance ETF (AIRR) focuses on small and mid-cap industrial companies involved in wiring, cooling, and powering hyperscale data centers. Its top holdings, including Comfort Systems, Sterling Infrastructure, ...
MidCap Financial Investment (MFIC) continues to experience a decline in its net asset value (NAV) and a shrinking portfolio, with total assets dropping from $3.46 billion to $2.86 billion year-over-year. Although MFIC maintains a stable dividend yiel...
Shares of Intuitive Machines surged 10% despite missing Q2 revenue and earnings estimates, driven by a record backlog of $1.8 billion and strong bookings. Virgin Galactic also gained 10% after bouncing back from a recent 8% drop caused by a delay in ...
StablecoinX, a Nasdaq-listed treasury company formed via a SPAC merger in June 2026, now holds about 3.029 billion ENA tokens, roughly 20% of Ethena's total 15 billion supply. This makes StablecoinX the largest single holder of ENA outside the protoc...
